Scarica l'app Stockscreener
42.63
2.89%
-1.27
Dopo l'orario di chiusura:
42.70
0.07
+0.16%
Precedente Chiudi:
$43.90
Aprire:
$43
Volume 24 ore:
1.70M
Relative Volume:
0.59
Capitalizzazione di mercato:
$5.73B
Reddito:
-
Utile/perdita netta:
$-237.54M
Rapporto P/E:
-17.03
EPS:
-2.5033
Flusso di cassa netto:
$-145.05M
1 W Prestazione:
-7.61%
1M Prestazione:
-7.29%
6M Prestazione:
+170.67%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$42.01
$43.74
Intervallo di 1 settimana:
$40.62
$47.55
Portata 52W:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
42.63 | 5.75B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-10 | Iniziato | Piper Sandler | Overweight |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - moomoo.com
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo
Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance
DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus
Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - marketbeat.com
DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance
DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - marketbeat.com
DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - marketbeat.com
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $90 - moomoo.com
Definium Phase III success with DT120 in anxiety - The Pharma Letter
Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - marketbeat.com
Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Australia
Canaccord raises Definium Therapeutics price target on trial data - Investing.com
DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus
RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - marketbeat.com
What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120? - Sahm
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha
DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus
Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - marketbeat.com
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView
Definium Therapeutics (NASDAQ:DFTX) Shares Gap UpWhat's Next? - marketbeat.com
Definium Therapeutics CEO Robert Barrow Acquires 375,000 Shares via Performance Share Units - Kalkine Media
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' - Benzinga
Definium Therapeutics Announces Positive Phase 3 Voyage Topline Results for DT120 ODT - Kalkine Media
Definium Therapeutics (DFTX) Shares Surge After Positive Phase 3 Trial; Valuation Hinges on Future Growth - GuruFocus
Form 8K Definium Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Definium Therapeutics stock jumps 20% on Phase 3 trial results By Investing.com - Investing.com Canada
Definium Therapeutics (DFTX) awards 62,500 performance-based shares to Chief Commercial Officer - Stock Titan
Definium Therapeutics (DFTX) awards CEO 375,000 performance-based shares - Stock Titan
Definium Therapeutics (DFTX) CFO receives 62,500-share performance-based equity grant - Stock Titan
Definium Therapeutics (DFTX) CLO awarded 62,500 performance-based shares in PSU tranche - Stock Titan
Wondering what's happening in today's pre-market session? - ChartMill
Definium Therapeutics posts positive Phase 3 Voyage topline: DT120 ODT cuts HAM-A by 5.4 pts vs placebo - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Definium Therapeutics (Nasdaq: DFTX) reports positive DT120 GAD Phase 3 data - Stock Titan
Definium Therapeutics shares surge after positive Phase 3 anxiety trial results - Yahoo Finance
Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo - marketscreener.com
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):